Skip to search formSkip to main contentSkip to account menu

obinutuzumab

Known as: Afutuzumab, Immunoglobulin G1, anti-(human CD20 (antigen)) (human-mouse monoclonal GA101 heavy chain), disulfide with human-mouse monoclonal GA101 KAPPA-chain, dimer, huMAB(CD20) 
A glycoengineered, humanized IgG1 monoclonal antibody with potential antineoplastic activity. Afutuzumab, a third generation type II anti-CD20… 
National Institutes of Health

Related topics

Related topics

11 relations
40 ML obinutuzumab 25 MG/ML Injection [Gazyva]Antibody-Dependent Cellular CytotoxicityB-LymphocytesCytotoxic T-Lymphocytes

Broader (2)

Antibodies, Monoclonal, HumanizedAntineoplastic Agents

Narrower (3)

GA 101GazyvaRO 5072759

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Initial results of a multicenter, investigator initiated study of MRD driven time limited therapy with zanubrutinib, obinutuzumab, and venetoclax.
8006Background: Venetoclax (Ven)-Obinutuzumab (O) is approved for chronic lymphocytic leukemia (CLL) achieving frequent… 
2019
2019
Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL).
DISCLOSURES Montegaard: Pharmacyclics: Consultancy; Janssen: Consultancy. Jacobson:Kite, a Gilead Company: Consultancy, Honoraria… 
2018
2018
Phase 2 Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia
BACKGROUND Development of targeted therapies for CLL including the anti-CD20 monoclonal antibody obinutuzumab (OBIN), Bruton's… 
2017
2017
Disseminated fusarium infection after ibrutinib therapy in chronic lymphocytic leukaemia
Review
2016
Review
2016
New monoclonal antibodies for the treatment of acute lymphoblastic leukemia.
2016
2016
Minimal Residual Disease in Patients with Follicular Lymphoma Treated with Obinutuzumab or Rituximab As First-Line Induction Immunochemotherapy and Maintenance in the Phase 3 GALLIUM Study
Background: Minimal residual disease (MRD) status reflects treatment efficacy and may predict prognosis after first-line therapy… 
Review
2016
Review
2016
Obinutuzumab or Rituximab Plus CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma: Final Results from an Open-Label, Randomized Phase 3 Study (GOYA)
Background: Rituximab (R) plus CHOP (R-CHOP) is standard-of-care treatment for previously untreated diffuse large B-cell lymphoma… 
2012
2012
GA101 (a Novel Anti-CD20 Monoclonal Antibody)-Induced Lichenoid Eruption
IntroductionObinutuzumab (GA101) is a novel anti-CD20 monoclonal antibody that has been shown to be effective for the treatment… 
Review
2011
Review
2011
Optimal Pharmacotherapeutic Management of Chronic Lymphocytic Leukaemia
Although the majority of patients with chronic lymphocytic leukaemia (CLL) are of advanced age, these patients have not been well… 
Review
2011
Review
2011
Randomized Phase II Trial Comparing GA101 (Obinutuzumab) with Rituximab in Patients with Relapsed CD20 Indolent B-Cell Non-Hodgkin Lymphoma: Preliminary Analysis of the GAUSS Study
Abstract 269 Background: GA101 is the first type II glycoengineered CD20 monoclonal antibody in phase II/III clinical trials for… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)